- Home
- GF vs ACRS Comparison
GF vs ACRS Comparison
Compare GF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- ACRS
- Stock Information
- Founded
- GF 1990
- ACRS 2012
- Country
- GF Germany
- ACRS United States
- Employees
- GF N/A
- ACRS N/A
- Industry
- GF Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- ACRS Health Care
- Exchange
- GF Nasdaq
- ACRS Nasdaq
- Market Cap
- GF 155.4M
- ACRS 127.6M
- IPO Year
- GF N/A
- ACRS 2015
- Fundamental
- Price
- GF $10.98
- ACRS $1.30
- Analyst Decision
- GF
- ACRS Strong Buy
- Analyst Count
- GF 0
- ACRS 7
- Target Price
- GF N/A
- ACRS $11.67
- AVG Volume (30 Days)
- GF 28.1K
- ACRS 832.4K
- Earning Date
- GF 01-01-0001
- ACRS 05-08-2025
- Dividend Yield
- GF 0.82%
- ACRS N/A
- EPS Growth
- GF N/A
- ACRS N/A
- EPS
- GF N/A
- ACRS N/A
- Revenue
- GF N/A
- ACRS $17,777,000.00
- Revenue This Year
- GF N/A
- ACRS N/A
- Revenue Next Year
- GF N/A
- ACRS $425.96
- P/E Ratio
- GF N/A
- ACRS N/A
- Revenue Growth
- GF N/A
- ACRS N/A
- 52 Week Low
- GF $7.38
- ACRS $0.95
- 52 Week High
- GF $9.41
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- GF 73.22
- ACRS 43.35
- Support Level
- GF $10.30
- ACRS $1.20
- Resistance Level
- GF $10.92
- ACRS $1.31
- Average True Range (ATR)
- GF 0.14
- ACRS 0.10
- MACD
- GF 0.07
- ACRS 0.02
- Stochastic Oscillator
- GF 98.57
- ACRS 43.04
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.